Skip to content
Log in
Sponsored AI AM CLAUDE, A Beginner's Guide: Learn the basics of working with AI AI AM CLAUDE, A Beginner's Guide: Learn the basics of working with AI

Author

A. Lazar

h-index 22 View on Semantic Scholar

We have 5 of 69 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Molecular landscape of hidradenoma and hidradenocarcinoma: associations with morphology and biology.

Our knowledge of the genomic landscape of hidradenocarcinoma (HACa), a rare, malignant sweat gland tumour that can arise de novo or from its benign counterpart, hidradenoma (HA), remains uncertain, and distinguishing between them can sometimes be challenging, as they can both present with conventional, clear cell or po...

I. Ferreira, J. Billington, M. del Castillo Velasco-Herrera et al. · 0 citations
Open access Oct 2026

Primary Breast Angiosarcoma: Clinicopathologic Features and Oncologic Outcomes.

BACKGROUND Primary breast angiosarcoma (PBA) is rare, and limited data exist because studies often combine primary and secondary angiosarcoma patients. METHODS For patients with PBA who received care at a comprehensive cancer center from 1991 to 2025 and underwent surgical resection, this retrospective study collecte...

Rick D. Vavolizza, A. Subramaniam, Min Yi et al. · 0 citations
Review Sep 2026

Management of Soft Tissue and Visceral Leiomyosarcomas.

Importance Leiomyosarcoma is a rare and heterogeneous malignant mesenchymal neoplasm associated with substantial morbidity and mortality. Given recent advances in biologic understanding and the complexity of leiomyosarcoma, a consensus-driven approach is needed to harmonize management and address remaining clinical and...

F. Campos, R. Gladdy, Annie Achee et al. · 0 citations
Open access Aug 2026

Panitumumab-Based EGFR Blockade in SMARCB1-Deficient Renal Medullary Carcinoma: Preclinical Basis and Prospective Clinical Activity

Purpose: SMARCB1-deficient renal medullary carcinoma (RMC) is an ultra-rare, lethal malignancy refractory to therapies approved for other renal cell carcinomas, and its rarity makes randomized trials logistically unfeasible. We investigated whether wild-type epidermal growth factor receptor (EGFR) is a therapeutically...

N. Zacharias, Eric S Rupe, Xinyue Chen et al. · 0 citations
Jul 2026

Abstract A027: Leveraging genomic copy-number complexity in uveal melanoma to drive novel therapeutic development

It is demonstrated that uveal melanoma progression reflects an integrated CN-transcriptional ecosystem extending beyond chromosome 3 loss, with cytoband-level genomic evolution shaping malignant fitness and therapeutic response.

Johnathon L. Rose, Sanjana Srinivasan, A. Cooper et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.